L iver transplantation has become an accepted therapy for end-stage liver disease and although the number of patients requiring liver transplants has risen significantly in recent years, the number of available donors has decreased. This shortage of suitable donor livers has led to the increasing use of so-called "marginal donors" (1-3). Transplantation of "marginal" donor livers is associated with an increased risk of primary nonfunction, increased retransplantation rates, and increased recipient morbidity and mortality (4, 5) . Liver steatosis (hepatic lipid accumulation) is a primary factor in determining the suitability of donor livers for transplantation, since donor liver steatosis is associated with a significantly increased risk of primary graft nonfunction (6 -8) . Currently, donor livers with Ͼ30% fat content are considered to have a prohibitively high rate of primary nonfunction and ϳ25% of donor livers are rejected due to steatosis. The pathogenic mechanisms for graft failure following transplantation of steatotic livers are incompletely understood, but there is evidence that steatotic livers are more susceptible to ischemia reperfusion injury (IRI) 4 (6 -8) . IRI is a major and unavoidable clinical problem associated with liver transplantation, whether donor livers are lean or steatotic. Activation of complement has been shown to occur in a number of organ systems following ischemia and reperfusion (I/R), and complement inhibition can be protective in animal models. With regard to hepatic IRI, studies using rat models have shown that complement depletion with cobra venom factor or complement inhibition with soluble CR, significantly reduce Kupffer cell activation, oxidative stress, neutrophil accumulation, microvascular dysfunction, and injury (9, 10) . C1 inhibitor has also been shown to reduce hepatic IRI in a rat model, indicating a role for the classical and/or lectin pathway of complement activation (10 -13) . In the single reported study that uses a mouse model of hepatic IRI to investigate the role of complement, the classical/lectin pathway is similarly implicated since transgenic mice overexpressing C1 inhibitor display reduced endothelial injury following hepatic I/R (14) . A role for C5a in hepatic IRI is indicated by the finding that C5a receptor antagonist treatment attenuates tissue injury following partial hepatic I/R in rats (15) . It is important to note that C3a and C5a also play important roles in liver regeneration, either through direct signaling or via their effects on cytokine production, and these C3 and C5 activation products may also have protective effects by promoting cellular regeneration and tissue repair following IRI (16 -18) .
In the current study, we investigated the role of complement in hepatic IRI and the increased susceptibility of steatotic livers to IRI and graft failure. For these studies, we used mice deficient in C3 and wild-type (wt) mice treated with the complement inhibitor CR2-Crry. CR2-Crry is a murine C3 convertase inhibitor that blocks all complement activation pathways and that targets to sites of complement activation. The targeting and the complement inhibitory activities of CR2-Crry have been previously characterized (19, 20) . Initial characterizations were performed using a model of warm total hepatic I/R, a procedure similar to the Pringle maneuver that is used to manage a variety of severe intraoperative complications. Complement deficiency and complement inhibition protected both lean and steatotic livers from warm IRI. To extend the study and place the findings in a clinically relevant context of transplantation, lean and steatotic livers were orthotopically transplanted and the therapeutic effect of complement inhibition in recipient mice was assessed.
Materials and Methods

Mice
Male C57BL/6 mice (The Jackson Laboratory) and C57BL/6 C3 Ϫ/Ϫ mice (in-house breeding colony) were housed in temperature-and light-controlled chambers on a 12-h light/dark cycle and provided with rodent chow (Purina 5001) and water ad libitum. At 4 wk of age, mice were either continued on normal diet or placed on a high-fat diet (34 g% fat, 60% kcal fat; Research Diets) for 4 wk to induce hepatic steatosis. Mice described as baseline did not undergo any surgery and were used for resting state measurements.
Surgical models
At 8 wk of age, following dietary treatment, wt lean, wt fat feed, C3 Ϫ/Ϫ lean, and C3 Ϫ/Ϫ fat feed mice were subjected to total warm hepatic ischemia as previously described (21) . Ischemia was performed for 45 min and surviving mice were sacrificed 24 h after reperfusion. Mouse orthotopic liver transplantation was performed as previously described (22) . For transplant model, 8-to 10-wk-old male lean or steatotic size-matched C57BL/6 mice were used. Time for the donor procedure averaged 30 min. The recipient operation averaged 45 min, and the portal vein clamp time averaged 15 min. Donor livers were stored for 3 h in cold saline before transplantation. Grafts were harvested for analysis at 6 and 24 h after transplant. Survival was monitored for 7 days after transplant, at which time the animals were sacrificed. There was no significant difference in operation time or ischemic times between groups. For complement inhibitor studies, wt recipients of lean or steatotic grafts were treated with either 0.25 mg of CR2-Crry or saline (vehicle control) by i.v. injection. All procedures were approved by the Medical University of South Carolina Committee for Animal Research in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals. The CR2-Crry fusion protein was produced and purified as described previously (19) .
Biochemical and immunological assays
Whole blood was collected from the right ventricle after thoractomy under anesthesia. Blood was allowed to clot at room temperature for 15 min and then centrifuged at 3500 ϫ g for 5 min at room temperature to collect serum. Serum levels of alanine aminotransferase (ALT) were determined using an autoanalyzer (Clinical Laboratory Services, Medical University of South Carolina) or using an analytical kit from Sigma-Aldrich according to the manufacturers' instructions. Serum levels of TNF-␣ and IL-6 were measured by ELISA using kits from eBioscience. For quantitative assessment of neutrophil infiltration into the liver parenchyma, liver myeloperoxidase (MPO) content was assessed using the Hbt mouse MPO ELISA Kit from Hycult Biotechnology according to the manufacturer's instructions.
Histology
H&E staining of liver sections was performed as previously described (21) . Sections stained with H&E were graded in a blinded fashion for centrilobular necrosis on a 0 -3 scale as described by Neil and Hubscher. (23) . Briefly, a grade of 0 indicated absent necrosis, 1 indicated individual hepatocyte dropout, 2 indicated small foci of missing hepatocytes up to two to three cells across, and 3 indicated confluent foci of hepatocyte dropout greater than three cells across. Ten high-powered fields per section were analyzed in relation to the central vein. Necrotic indexing was performed in a blinded fashion.
Complement activation
Complement activation was assessed in liver samples after IRI by immunohistochemical localization of C3d and by Western blot analysis of the complement activation fragment C3a. For immunohistochemistry, paraffin-embedded sections of livers were stained for complement (C3d; DakoCytomation) as previously described (19) . For Western blot analysis, liver samples were homogenized and protein was extracted as previously described (24) . Protein samples were separated by electrophoresis on a 4 -20% gradient SDS-PAGE gel. Protein concentration was confirmed using the Bradley method (24) , and equal amounts of total protein were added to each lane. To further verify that protein loading was equal, membranes were additionally probed with GAPDH. Following transfer to nitrocellulose membranes, blots were blocked with TBS-Tween 20 containing 5% dry milk for 1 h at room temperature. Blots were washed three times with TBS-Tween 20 and then incubated with anti-C3a-biotinylated (BD Biosciences) or GADPH (Santa Cruz Biotechnology) primary Ab in TBSTween 20 for 2 h at room temperature. C3a blots were washed three times with TBS-Tween 20 and incubated with streptavidin-biotin-HRP secondary Ab (BD Biosciences) for 1 h before visualization with ECL substrate reagent (Bio-Rad). GADPH blots were washed three times with TBSTween 20 and incubated with a secondary Ab (Santa Cruz Biotechnology) conjugated with HRP for 1 h and then visualized with ECL substrate reagent. Quantification of Western blots was performed using a Bio-Rad Molecular Imager Gel Doc.
Liver steatosis
The degree of liver steatosis was quantified by Oil Red O staining and by measurement of total liver triglycerides. Oil Red O staining was performed as previously described (25) and the percentage of steatosis was calculated using computerized image analysis with the Leica Microsystems Qwin Image analysis software. Total liver triglyceride levels were measured using a triglyceride reagent kit according to the manufacturer's instructions (Pointe Scientific).
Statistical analysis
Data are expressed as mean Ϯ SD. Statistical analysis was conducted using SPSS software (version 6.0). Significant differences between groups were determined by ANOVA, and p Ͻ 0.05 was considered significant. All histological statistical analyses were conducted using nonparametric twotail analysis and p Ͻ 0.05.
Results
Characterization of steatosis
C3 contributes to ethanol-induced steatosis in mice, and C3-deficient mice fed an ethanol diet do not develop steatosis (26 -28) . We therefore characterized the effect of a high fat diet on liver steatosis in wt and C3 Ϫ/Ϫ mice. Both wt and C3 Ϫ/Ϫ mice responded comparably to the high fat diet and hepatic steatosis was similarly induced in both groups of mice as quantified by body weight indices, intrahepatic lipid, triglyceride content of livers, and serum ALT levels (results summarized in Table I ). Qualitatively, the pattern and distribution of fat deposits was similar in wt and C3
Ϫ/Ϫ mice fed a high fat diet, with moderate to severe macrovesicular steatosis and mild microvesicular steatosis, as demonstrated by H&E staining of sections ( Fig. 1) . Quantification of lipid content by Oil Red O staining and by assay of total hepatic triglyceride were also similar in fat-fed wt and C3 Ϫ/Ϫ mice (Table I and Fig.  1 ). There was no lipid detectable by Oil Red O staining in lean wt or C3
Ϫ/Ϫ mice and hepatic triglyceride levels were Ͻ5% (data not shown). We also measured baseline levels of ALT in wt and C3
Ϫ/Ϫ fat-fed animals, since liver steatosis is associated with raised levels of this enzyme. There was an apparent increase in baseline ALT levels in fat-fed mice compared with lean mice, but the increase was not statistically significant ( p Ͼ 0.05). Finally, body weight analysis revealed no significant difference in weight gained by either wt or C3 Ϫ/Ϫ mice given a high fat diet, and liver body weight ratios between wt and C3 Ϫ/Ϫ mice were also not significantly different (Table I) .
Warm hepatic I/R model and experimental groups
Animals were subjected to 45 min of total warm hepatic ischemia followed by 24 h of reperfusion, at which time survival, liver injury, and local inflammation were assessed. In all, six experimental groups were evaluated: lean and steatotic (fat-fed) wt mice, lean and steatotic C3 Ϫ/Ϫ mice, and lean and steatotic wt mice treated with the complement inhibitor CR2-Crry (0.25 mg i.p.,10 min after reperfusion). A model of total ischemia was used because of its relevance to liver transplantation.
Survival and liver function following I/R
All lean mice (wt, C3
Ϫ/Ϫ , and CR2-Crry treated) survived for 24 h following hepatic I/R. In contrast, only 33% (5 of 15) of wt steatotic mice survived 24 h following I/R. However, C3 deficiency conferred complete protection to steatotic mice in terms of survival (10 of 10 survived) and 87.5% (seven of eight) of CR2-Crrytreated steatotic mice survived (Fig. 2) . Increased serum ALT levels that occur following hepatic I/R are indicative of liver injury, and ALT levels were analyzed 24 h after reperfusion in surviving animals from all six groups. There was no significant difference between baseline levels of ALT (preischemic) in steatotic wt, steatotic C3 Ϫ/Ϫ , lean wt, and lean C3 Ϫ/Ϫ mice ( p Ͼ 0.05). However, postreperfusion levels of ALT in wt lean mice were significantly increased over baseline (Fig. 3) . Levels of ALT were also increased above baseline in C3
Ϫ/Ϫ and CR2-Crry-treated lean mice, but the increase was significantly less than that seen in untreated wt mice (Fig. 3) . Postreperfusion levels of ALT were significantly higher in all steatotic animals compared with their lean counterparts. However, as with lean mice, complement deficiency and complement inhibition in steatotic mice resulted in significantly reduced ALT levels when compared with increases seen in steatotic untreated wt mice. Although C3 deficiency/inhibition significantly reduced ALT levels in steatotic mice compared with their wt counterparts, levels were still significantly higher than those seen in wt lean animals. All ALT determinations were made at 24 h after reperfusion to study survival in the same animal groups. Although the relative differences in ALT levels is the significant finding here, it is of note that the actual levels are lower than would be expected at 6 h when ALT levels peak in this model. Nevertheless, the ALT levels at 24 h in the model used here are close to previously reported ranges (21) . 
Histopathology following I/R
There was centrilobular necrosis in all lean groups at 24 h after reperfusion, but complement deficiency and complement inhibition with CR2-Crry was associated with a significantly lower injury score when compared with wt lean animals (Fig. 4A ). There was also centrilobular necrosis in all steatotic groups, but again complement deficiency and complement inhibition were associated with a significantly lower injury score when compared with wt animals (Fig. 4A) . Wild-type steatotic livers were significantly more susceptible to IRI than wt lean livers as assessed histologically. Of note, however unlike ALT levels, there was no significant difference between the extent of damage seen in lean and steatotic livers when complement was deficient or inhibited. Representative images of H&E-stained sections from steatotic livers after reperfusion are shown in Fig. 4 , B-D. Liver samples from normal (preischemic) mice showed no evidence of centrilobular necrosis (data not shown).
Complement deposition and activation following I/R
The deposition and distribution of C3 was assessed in lean and steatotic wt mice 24 h after reperfusion by immunohistochemistry. C3d was deposited on hepatocyte membranes, sinusoidal endothelium, and Kupffer cells within livers that had undergone I/R (Fig.  5, A and B) . Staining for C3d was more intense in centrilobular areas, corresponding to areas of increased liver damage as determined by H&E staining (above). The distribution of C3d was similar in steatotic and lean livers, but C3d deposition in centrilobular areas of steatotic livers appeared to involve more hepatocytes and to spread deeper into the liver away from the centrilobular area. However, although C3d staining of viable cells appeared to be greater in steatotic compared with lean livers, this finding should be interpreted with caution. Staining of lean and steatotic livers with isotype control Abs, as well as staining in C3 Ϫ/Ϫ animals, resulted in some nonspecific staining, and nonspecific staining was more intense in steatotic livers. Therefore, we cannot rule out the possibility that the increase in C3d staining intensity seen in steatotic livers was due not only to an increase in centrilobular damage, but was also associated with an increase in nonspecific staining associated with fat deposition. We therefore assessed whether steatosis was associated with increased complement activation by assay of the C3 activation fragment C3a in liver homogenates. Samples from lean and steatotic livers isolated from both controltreated and CR2-Crry-treated mice were analyzed by Western blot and densitometry. C3a was barely detectable in liver samples from sham-operated mice, but was readily detected in postreperfusion samples from lean and steatotic livers, with significantly higher levels in steatotic livers (Fig. 5, C and D) . Furthermore, treatment of either lean or steatotic animals with CR2-Crry resulted in a significant reduction in C3a levels compared with their PBStreated counterparts, a result that correlates with decreased C3d deposition seen in CR2-Crry-treated mice (Fig. 5, C and D) . All C3a semiquantitative densitometry results are normalized to GADPH density.
Orthotopic liver transplantation model and experimental groups
The foregoing data demonstrate that complement plays an important role in hepatic injury following warm I/R and that complement contributes to the enhanced susceptibility of steatotic livers to warm I/R. To extend these studies and investigate the role of complement in IRI in a clinical setting of transplantation, we investigated the effect of complement inhibition in recipients of lean and steatotic liver grafts. Following transplantation of livers, lean recipient mice were treated with either saline or CR2-Crry (0.25 mg) immediately after implantation of liver. Grafts were isolated at either 6 or 24 h after transplantation and analyzed for liver injury and inflammation. Survival of recipient mice was also monitored for 7 days. In all, four experimental groups were evaluated: lean graft-to-lean recipient, saline treated; lean-to-lean, CR2-Crry treated; steatotic-to-lean, saline treated; and steatotic-to-lean, CR2-Crry treated.
Graft injury following liver transplantation
Following transplantation, there was a significant increase in recipient serum ALT levels in all groups compared with baseline, and recipients of steatotic grafts had significantly higher levels of ALT than recipients of lean grafts (Fig. 6A) . However, compared with saline-treated controls, CR2-Crry treatment resulted in a significant reduction of ALT levels in recipients of both lean and steatotic grafts, both at 6 and 24 h after transplantation (Fig. 6A) . Of note, complement inhibition in recipients of steatotic grafts reduced serum ALT to levels at or below those seen in untreated recipients of lean grafts.
In keeping with our observations in the IRI model, centrilobular hepatocyte necrosis was evident in both lean and steatotic grafts at 6 and 24 h after transplantation. However, compared with the IRI model, the degree of hepatic damage was increased in the transplant model, with necrosis expanding beyond the centrilobular areas. Quantitative assessment of the histological damage demonstrated a marked protective effect associated with complement inhibition; there was excessive hepatic necrosis in both lean and steatotic grafts isolated from saline-treated recipients, but not in Ϫ/Ϫ mice and significantly reduced in wt mice treated with CR2-Crry. B, Immunohistochemistry staining of livers from steatotic mice. C3d deposition is similarly localized to centrilobular areas in wt steatotic mice and is associated with hepatocyte damage. In steatotic C3 Ϫ/Ϫ mice, a low level of nonspecific C3d staining was associated with fat accumulation. Staining is reduced in CR2-Crry-treated steatotic mice compared with wt mice. Images representative, n ϭ 5, and magnification indicated by scale bars. C, Western blot analysis of C3a and GADPH in liver homogenates 24 h after I/R. Shown is a representative blot and densitometric analysis (mean intensity per mm 2 Ϯ SD, n ϭ 3). C3a levels were higher in wt steatotic livers compared with lean livers, and CR2-Crry treatment significantly reduced C3a levels in both lean and steatotic mice. Results are expressed as intensity per mm 2 normalized to GADPH expression. #, p Ͻ 0.05 vs wt counterparts and ‫,ء‬ p Ͻ 0.05 vs lean. Mean Ϯ SD, n ϭ 3.
grafts isolated from CR2-Crry-treated recipients (Fig. 6B) . Of note, CR2-Crry afforded a similar level of protection to both lean and steatotic grafts.
Inflammation in graft following liver transplantation
Complement activation products are known to play important roles in leukocyte recruitment, vascular adherence, and cytokine production, and a role for neutrophils and cytokines (particularly TNF-␣ and IL-6) in hepatic IRI is well documented (29 -32) . To assess the effect of complement activation on neutrophil infiltration, MPO levels in liver homogenates were determined. Levels of MPO were elevated in all posttransplant samples compared with baseline and sham-operated controls but, in correlation with measurements of hepatic injury, complement inhibition reduced MPO levels in recipients of both lean and steatotic grafts (Fig. 7) . TNF-␣ and IL-6 was undetectable in lean and steatotic sham controls, but both cytokines were elevated in all recipient mice at 6 and 24 h after transplant, and cytokine levels were higher in recipients of steatotic grafts compared with recipients of lean grafts. Complement inhibition, however, significantly reduced the levels of both cytokines when compared with their lean and steatotic counterparts at both time points (Fig. 8) . Of note, in saline-treated recipients of lean grafts, MPO and cytokine levels at 24 h after transplant were similar or decreased compared with levels at 6 h after transplant. However, in saline-treated recipients of steatotic grafts, MPO and cytokine levels were increased at 24 h after transplant, indicating exacerbated and prolonged inflammation in the steatotic grafts. Overall, CR2-Crry treatment reduced the inflammatory profile in recipients of steatotic grafts to a level similar to that in saline-treated recipients of lean grafts.
Immunohistochemistry revealed C3d deposition in a similar distribution to that seen in the warm IRI model, with C3d deposited on hepatocytes, sinusoidal endothelium, and Kupffer cells. The staining intensity was more prominent in steatotic livers than in lean livers and was undetectable in livers from CR2-Crry-treated mice at both 6 and 24 h after transplantation (data not shown).
Recipient survival following liver transplantation
Clinical data has shown that steatotic grafts are associated with an increased risk of primary nonfunction and increased recipient morbidity and mortality. In agreement with clinical findings, steatotic livers were more susceptible to graft failure than lean livers, and this was regardless of whether recipient mice were treated with CR2-Crry (Fig. 9) . However, complement inhibition in recipients of both lean and steatotic grafts was associated with a significant improvement in posttransplant survival when compared with saline-treated counterparts. These data show that the level of complement-dependent inflammation and injury observed in lean and FIGURE 6. Effect of CR2-Crry treatment on liver injury in recipients of lean and steatotic grafts. A, ALT levels at 6 and 24 h after transplantation. Recipients of either lean or steatotic donor livers were treated with saline or 0.25 mg of CR2-Crry immediately after surgery. ALT levels were significantly increased in all steatotic groups compared with lean counterparts (##, p Ͻ 0.05). Compared with saline treatment, CR2-Crry treatment significantly reduced ALT levels in recipients of either lean or steatotic grafts ‫,ء(‬ p Ͻ 0.05). Mean Ϯ SD, n ϭ 6 in each group. B, Histological injury score at 6 and 24 h after transplantation. There is increased injury to steatotic grafts compared with lean grafts in saline-treated recipients at 24 h after transplant (##, p Ͻ 0.05), but not at 6 h after transplant. CR2-Crry treatment reduced injury to both lean and steatotic grafts at both time points of analysis ‫,ء(‬ p Ͻ 0.05), and there was no significant difference between injury scores for lean and steatotic grafts at either time point. There was no evidence of damage in baseline donor animals. Mean Ϯ SD, n ϭ 6 in each group.
FIGURE 7.
Neutrophil infiltration of grafts. Lean or steatotic grafts were isolated from saline-or CR2-Crry-treated recipients at 6 or 24 h after transplantation. Neutrophil activity in liver homogenates was estimated by assessing MPO activity. MPO levels in steatotic grafts were increased compared with lean grafts (#, p Ͻ 0.05). Treatment of recipients with CR2-Crry resulted in a significant reduction in MPO levels in both lean and steatotic grafts compared with saline-treated recipients ‫,ء(‬ p Ͻ 0.05). Mean Ϯ SD, n ϭ 6 in each group. steatotic grafts following transplantation (as shown above) correlates with graft failure and support the concept that complement inhibition may represent a strategy to permit expanded use of marginal steatotic livers.
Discussion
Ischemia and reperfusion of a donor organ following transplantation results in an inflammatory response that causes acute injury and may also increase graft immunogenicity and alloresponsiveness of the recipient (33, 34) . Steatosis significantly increases the susceptibility of livers to IRI. The pathogenic mechanisms involved in IRI are complex and multifaceted, but studies using animal models have shown that activation of complement is a key initiating event in IRI of various organs and tissues (35) (36) (37) (38) . In our initial studies, we demonstrated that C3 deficiency or complement inhibition at the C3 activation step protects against hepatic IRI in a mouse model of warm I/R. Furthermore, using the same model with fat-fed mice, we showed that the enhanced susceptibility of steatotic livers to IRI was reversed by complement deficiency or inhibition. We used a model of total hepatic ischemia because of its relevance to liver transplantation, although we have also shown that complement deficiency and inhibition protects against IRI in a model of partial hepatic ischemia that does not carry the risk of venous portal congestion and endotoxemia (our unpublished data).
Thus, data obtained using the total hepatic IRI model suggests that complement inhibitor therapy may represent a strategy to increase the donor pool, since ϳ25% of donor livers are currently rejected due to steatosis (livers with Ͼ30% steatosis are usually rejected as donor organs). Therefore, to put our findings in a more clinically relevant context, we investigated the effect of complement inhibition in a model of orthotopic liver transplantation in which lean recipients received either lean or steatotic grafts. There was increased injury and increased and prolonged inflammation in steatotic grafts compared with lean grafts, and in keeping with the bulk of clinical data, steatosis was associated with increased graft failure. CR2-Crry administered to recipients protected both lean and steatotic grafts from injury and graft failure, and the protective effect of complement inhibition correlated with a reduced inflammatory profile.
Since the extent of steatosis is positively associated with the extent of IRI (7, 8, 39, 40) , and the C3 activation product C3adesArg (also known as acylation-stimulating protein) is involved in the regulation of lipid metabolism (41, 42) , a possible explanation for the reduced level of hepatic IRI seen in C3 Ϫ/Ϫ mice is that C3 Ϫ/Ϫ mice develop less liver steatosis. However, following a 4-wk high fat diet (60% calories from fat), we detected no significant quantitative or qualitative differences in steatosis between wt and C3 Ϫ/Ϫ mice. Also, the fact that complement inhibition in wt steatotic mice is protective in the IRI model further argues against any inherent increased susceptibility of C3 Ϫ/Ϫ mice to the high fat diet. It is of note, nevertheless, that C3 Ϫ/Ϫ mice do not develop ethanol-induced hepatic steatosis (26 -28) , and the role of complement in the development of steatosis can thus be dependent on the inducing factor. There is also a report that a high fat diet does not produce steatosis in wt (C3 ϩ/ϩ ) C57BL/6 mice, but a different diet was used (28) . Indeed, numerous previous studies have shown that the high fat diet used in the current study results in hepatic steatosis in C57BL/6 mice. We show that macrovesicular steatosis predominates in both wt and C3 Ϫ/Ϫ fat-fed mice, and although not completely without controversy, macrovesicular steatosis rather than microvesicular steatosis is considered a risk factor for primary graft dysfunction following transplantation (5, 39, 43) . Livers with macrovesicular steatosis have also A, IL-6 serum levels at 6 and 24 h after transplantation. IL-6 is significantly increased in recipients of steatotic livers compared with recipients of lean livers (##, p Ͻ 0.05). Compared with saline, CR2-Crry treatment significantly reduced IL-6 levels in both lean ‫,ء(‬ p ϭ 0.001 and 0.001 at 6 and 24 h, respectively) and steatotic ‫,ء(‬ p ϭ 0.008 and 0.001 at 6 and 24 h, respectively) grafts. Mean Ϯ SD, n ϭ 6 in each group. B, TNF-␣ serum levels at 6 and 24 h after transplantation. TNF-␣ is significantly increased in recipients of steatotic livers compared with recipients of lean livers (##, p Ͻ 0.05). Compared with saline, CR2-Crry treatment significantly reduced TNF-␣ levels in both lean ‫,ء(‬ p ϭ 0.007 and 0.004 at 6 and 24 h, respectively) and steatotic ‫,ء(‬ p ϭ 0.007 and 0.001 at 6 and 24 h, respectively) mice. Mean Ϯ SD, n ϭ 6 in each group. FIGURE 9. Graft survival. recipients of lean or steatotic grafts were treated with saline or CR2-Crry immediately after implantation. CR2-Crry treatment significantly improved 7-day survival for recipients of both lean and steatotic grafts (p ϭ 0.0023 for lean CR2-Crry vs saline, and p ϭ 0.047 for steatotic CR2-Crry vs saline). n ϭ 8 in each group. been shown to be more susceptible to injury than livers with microvesicular steatosis in a mouse model of hepatic IRI, a finding that correlated with significantly lower hepatic perfusion and portal vein flow in macrosteatotic livers (40) . Macrovesicular steatosis, as induced by diet and insulin, is more common within the donor population, whereas, microvesicular is more commonly associated with drugs, toxins, and metabolic disorder (44) .
Previous studies have demonstrated the presence of complement in the ischemically injured liver, with complement deposition on hepatocytes and sinusoidal endothelial cells, cells that are reported to express low levels of complement regulatory proteins (12, 45) . We similarly demonstrated the presence of C3d on hepatocytes and the sinusoidal endothelium in wt lean and steatotic mice after I/R and after transplantation. The pattern of staining was similar in both lean and steatotic livers, although the frequency and intensity of complement deposition appeared to be increased in steatotic liver samples. The increased complement deposition is likely related to the increased damage seen in steatotic livers after reperfusion. We did not attempt to quantify the increase in staining intensity in steatotic livers, since there was an increase in nonspecific staining in these livers as evidenced by staining for C3d in C3
Ϫ/Ϫ and CR2-Crry-treated animals. Furthermore, previous studies have reported that steatotic livers produce increased levels of complement proteins de novo (46) , which may also contribute to the apparent increase in C3d immunostaining. Nevertheless, CR2-Crry treatment resulted in a significant reduction in immunostaining for C3d in livers from both lean and steatotic mice after I/R and posttransplantation. Taken together, these data suggest that steatosis results in exacerbated complement activation and may contribute to an increased susceptibility to IRI. We therefore quantified complement activation in lean and steatotic livers by measuring the complement activation fragment C3a. Following IRI, steatotic livers were associated with significantly higher hepatic concentrations of C3a than lean livers.
Steatotic livers were similarly more susceptible to injury than lean livers in the transplant and warm ischemia models, as determined by ALT levels and histological injury score. In the transplant model, we analyzed two time points after IRI (6 and 24 h) and demonstrated that ALT levels were significantly elevated at both time points in both lean and steatotic livers compared with sham controls, although ALT levels were reduced at 24 h compared with 6 h. This trend was not seen for histological injury score and there was evidence of elevated necrosis in steatotic grafts at 24 h compared with 6 h. It is difficult to reconcile these opposite trends seen for ALT levels and histological injury. It is possible that this may be related to the dynamics of injury, with cellular injury that leads to the release of ALT occurring early after IRI, and histological evidence of hepatic necrosis occurring progressively, a process that may be delayed in with hepatic steatosis. In this regard, hepatic steatosis has been shown to affect the metabolic functions of the liver and it is possible that metabolic constraints delay the appearance of histologically detectable necrosis.
Data from the transplantation model show that the increased failure of steatotic grafts compared with lean grafts is associated with a significantly higher inflammatory burden (C3a, MPO, TNF-␣, and IL-6 levels). Furthermore, the improved survival rate of recipients treated with CR2-Crry was associated with a significant reduction in inflammatory burden, whether the transplanted graft was lean or steatotic. Together with the activation of Kupffer cells and neutrophil infiltration, the inflammatory cytokines TNF-␣ and IL-6 have been implicated in mediating hepatic injury following I/R via various mechanisms (for reviews, see Refs. 47-49). However, TNF-␣ and IL-6 also play key roles in hepatocyte proliferation and thus appear to have dual functions by participating in both inflammation/injury and regeneration. Complement activation products C3a and C5a have been shown to play an essential role in the early priming phase of hepatocyte regeneration via induction of TNF-␣ and IL-6 expression and subsequent NF-B and STAT-3 activation (17) . Indeed, complement deficiency or complement inhibition significantly impairs liver regeneration and increases mortality in models of partial hepatectomy or toxic injury (16, 17) . It is not clear to what extent the regenerative response is necessary for cellular repair and recovery following IRI, although studies in transplant models indicate that the regenerative response and expression of TNF-␣ and IL-6 become more important to graft recovery as cold storage time is increased (16, 17) . However, in the current study, in a setting of full-size liver transplantation (and 3 h cold storage), complement inhibition has clear benefits regarding graft function and survival. Although the cytokine data is only correlative, a contributing protective mechanism of complement inhibition may be the modulation of TNF-␣-and IL-6-dependent pathways of hepatocellular injury. Regardless, the protective effect of complement appears to outweigh any potential benefit that increased expression of the cytokines may have on hepatocyte regeneration and graft recovery (for both lean and steatotic grafts).
In conclusion, the current data demonstrate an important role for complement in the enhanced susceptibility of steatotic livers to IRI and suggest that complement inhibition represents a therapy that may enable the expanded use of so-called marginal steatotic livers for transplantation. In this context, the CR2-mediated targeting strategy used here for complement inhibition not only significantly increases the efficacy of the linked complement inhibitor, but also minimizes immune suppression that is associated with systemic complement inhibition (19) , a potentially important benefit for a transplant recipient.
